Evidence map›Paper›PMID 39098868›Full record

ArticleNPJ breast cancer2024

Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ.

Heather I Greenwood, Cristian K Maldonado Rodas, Rita I Freimanis, Alexa C Glencer, Phoebe N Miller, Rita A Mukhtar, Case Brabham, Christina Yau, Jennifer M Rosenbluth, Gillian L Hirst and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ breast cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Heather I Greenwood *University of California San Francisco Department of Radiology, San Francisco, CA, USA.
Cristian K Maldonado Rodas *University of California San Francisco Department of Surgery, San Francisco, CA, USA.
Rita I FreimanisUniversity of California San Francisco Department of Radiology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-5229-8687
Alexa C GlencerUniversity of California San Francisco Department of Surgery, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-3183-1056
Phoebe N MillerUniversity of California San Francisco Department of Surgery, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-3938-3606
Rita A MukhtarUniversity of California San Francisco Department of Surgery, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-8079-7846
Case BrabhamHarvard Medical School, Boston, MA, USA.
Christina YauUniversity of California San Francisco Department of Surgery, San Francisco, CA, USA.
Jennifer M RosenbluthUniversity of California San Francisco Department of Medicine, San Francisco, CA, USA.
Gillian L HirstUniversity of California San Francisco Department of Surgery, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-4502-0035
Michael J CampbellUniversity of California San Francisco Department of Surgery, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-3788-9240
Alexander BorowskyUniversity of California Davis Department of Pathology, Sacramento, CA, USA.ORCID http://orcid.org/0000-0003-3117-9202
Nola HyltonUniversity of California San Francisco Department of Radiology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-6747-1662
Laura J EssermanUniversity of California San Francisco Department of Surgery, San Francisco, CA, USA. laura.esserman@ucsf.edu.ORCID http://orcid.org/0000-0001-9202-4568
Amrita BasuUniversity of California San Francisco Department of Surgery, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-5362-1343

Funding

Elucidating the molecular and contextual basis for IDLE ultralow risk lesions and the tumor immune microenvironment of high risk in situ and invasive breast cancersU01CA196406 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOROWSKY, ALEXANDER D, ESSERMAN, LAURA J · 2015 to 2020
$5.8M
Surgical Oncology Training GrantT32CA251070 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ESSERMAN, LAURA J · 2020 to 2024
$1.5M
NCI NIH HHS T32 CA251070NCI NIH HHS U01 CA196406U.S. Department of Health & Human Services | National Institutes of Health (NIH) T32CA251070-01U.S. Department of Health & Human Services | National Institutes of Health (NIH) U01CA196406
6 · The paper itself

Abstract

New approaches are needed to determine which ductal carcinoma in situ (DCIS) is at high risk for progression to invasive ductal carcinoma (IDC). We retrospectively studied DCIS patients who declined surgery (2002-2019), and received endocrine therapy (ET) and breast MRI. Baseline MRI and changes at 3 months and 6 months were analyzed by recursive partitioning to stratify IDC risk. Sixty-two patients (63 DCIS; 1 bilateral) with a mean follow-up of 8.5 years were included. Fifty-one percent remained on active surveillance (AS) without evidence of IDC, with a mean duration of 7.6 years. A decision tree based on MRI features of lesion distinctness and background parenchymal enhancement (BPE) at baseline and change after 3 months of ET stratified patients into low, intermediate, and high risk for progression to IDC. MRI imaging features in patients treated with ET and undergoing AS, may help determine which DCIS lesions are at low versus high risk for IDC.

Identifiers

PMID39098868
PMCPMC11298531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.